RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adaptimmune Therapeutics Stock

Adaptimmune Therapeutics ROE 2025

Adaptimmune Therapeutics ROE

-5.98

Ticker

ADAP

ISIN

US00653A1079

WKN

A14SUX

In 2025, Adaptimmune Therapeutics's return on equity (ROE) was -5.98, a 107.38% increase from the -2.88 ROE in the previous year.

Adaptimmune Therapeutics Aktienanalyse

What does Adaptimmune Therapeutics do?

Adaptimmune Therapeutics PLC is a biotechnology company specializing in the development of immunotherapies against cancer. The company was founded in 2008 and is headquartered in Oxfordshire, England. Adaptimmune focuses on harnessing the human immune system to target and destroy cancer cells. The company's business model primarily revolves around the research and development of therapeutic products for different types of cancer. It develops and utilizes T-cell receptor (TCR) therapies to specifically target cancer cells. TCRs are proteins on T-cells that can recognize and kill cancer cells. Adaptimmune harnesses this property of TCRs to develop specific receptors targeted against certain types of cancer. Adaptimmune has three different business segments: oncology, autoimmune diseases, and infections. However, the focus is primarily on oncology. In this area, Adaptimmune concentrates on developing TCR products for various types of cancer such as pancreatic cancer, esophageal cancer, and lung cancer. One of Adaptimmune's key products is the T-cell therapy known as SPEAR (Specific Peptide Enhanced Affinity Receptor), which is individually developed for each patient. This therapy utilizes TCRs targeting specific tumor cells. The TCRs are optimized so that the body's own T-cells can precisely recognize and destroy the cancer cells. SPEAR has already shown promising results in a clinical study for melanoma patients. Another important product of Adaptimmune is ADP-A2M4. This immunotherapy also utilizes TCRs developed to target specific cancer cells. ADP-A2M4 is currently in Phase II clinical trials for advanced or metastatic esophageal cancer or gastric cancer. Adaptimmune also has partnerships with other companies and organizations such as GSK, NY-ESO-1, Universal Cells, and the MD Anderson Cancer Center. This collaboration expands the company's portfolio and enables the development of innovative immunotherapies. Overall, Adaptimmune's goal is to develop innovative TCR products for the treatment of various types of cancer. With its focus on immunotherapies, the company has created unique solutions to mobilize the human immune system specifically against cancer. Adaptimmune has the potential to revolutionize cancer treatment and improve the lives of millions of people. Adaptimmune Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Adaptimmune Therapeutics's Return on Equity (ROE)

Adaptimmune Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Adaptimmune Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Adaptimmune Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Adaptimmune Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Adaptimmune Therapeutics stock

What is the ROE (Return on Equity) of Adaptimmune Therapeutics this year?

The ROE of Adaptimmune Therapeutics this year is -5.98 undefined.

How has the Return on Equity (ROE) of Adaptimmune Therapeutics developed compared to the previous year?

The ROE of Adaptimmune Therapeutics has increased by 107.38% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Adaptimmune Therapeutics?

A high ROE indicates that Adaptimmune Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Adaptimmune Therapeutics?

A low ROE can indicate that Adaptimmune Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Adaptimmune Therapeutics affect the company?

A change in ROE (Return on Equity) of Adaptimmune Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Adaptimmune Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Adaptimmune Therapeutics?

Some factors that can influence Adaptimmune Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Adaptimmune Therapeutics pay?

Over the past 12 months, Adaptimmune Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptimmune Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptimmune Therapeutics?

The current dividend yield of Adaptimmune Therapeutics is .

When does Adaptimmune Therapeutics pay dividends?

Adaptimmune Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptimmune Therapeutics?

Adaptimmune Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Adaptimmune Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptimmune Therapeutics located?

Adaptimmune Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptimmune Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptimmune Therapeutics from 7/22/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/22/2025.

When did Adaptimmune Therapeutics pay the last dividend?

The last dividend was paid out on 7/22/2025.

What was the dividend of Adaptimmune Therapeutics in the year 2024?

In the year 2024, Adaptimmune Therapeutics distributed 0 USD as dividends.

In which currency does Adaptimmune Therapeutics pay out the dividend?

The dividends of Adaptimmune Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Adaptimmune Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Adaptimmune Therapeutics

Our stock analysis for Adaptimmune Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptimmune Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.